Livet Wealth LLC purchased a new position in Astrazeneca Plc (NYSE:AZN – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,710 shares of the company’s stock, valued at approximately $651,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Kestra Investment Management LLC lifted its stake in Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Luken Investment Analytics LLC lifted its stake in Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares during the period. Addison Advisors LLC lifted its stake in Astrazeneca by 3.9% in the fourth quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock worth $305,000 after acquiring an additional 65 shares during the period. Western Wealth Management LLC lifted its stake in Astrazeneca by 2.5% in the fourth quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after acquiring an additional 71 shares during the period. Finally, Soltis Investment Advisors LLC lifted its stake in Astrazeneca by 2.2% in the fourth quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $609,000 after acquiring an additional 76 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca Stock Performance
Shares of Astrazeneca stock opened at $178.79 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $277.28 billion, a P/E ratio of 26.85, a P/E/G ratio of 1.59 and a beta of 0.25. The business has a fifty day simple moving average of $189.26 and a two-hundred day simple moving average of $185.90. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71.
Wall Street Analyst Weigh In
Several equities analysts have commented on AZN shares. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $205.33.
Check Out Our Latest Report on Astrazeneca
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
